Renal Failure News
Bayer announces plan to completely pull Trasylol from the market
Bayer AG says that it will completely remove all remaining supplies of its heart surgery drug Trasylol from the U.S. market. The decision to issue the Trasylol recall was made following the publication of a new study which found that the drug could significantly increase a patient’s risk of death compared with two cheaper alternatives.
Scientist blames as many as 22,000 deaths on Trasylol
A leading medical researcher says that as many as 22,000 lives could have been saved if U.S. regulators have moved more quickly to recall the heart surgery drug Trasylol. Bayer AG, the manufacturer of the drug, suspended marketing of Trasylol in November 2007 after the preliminary results of a Canadian study revealed an increased risk of death and other Trasylol side effects.
Studies confirm Trasylol death, kidney failure risk
Two new studies have confirmed that the heart surgery drug Trasylol can increase patients’ risk of death and kidney damage. The drug is given to patients during heart surgery in order to prevent bleeding. Bayer AG, the manufacturer of Trasylol, suspended its marketing of the drug in November 2007 when the preliminary results from a Canadian drug trial revealed an increased risk of Trasylol side effects.
FDA panel chairman says he would have voted to pull Trasylol
The chairman of a Food and Drug Administration advisory panel says that he would have voted to pull the heart surgery drug Trasylol off the market if he had known about the existence of a study highlighting the risk of Trasylol side effects. Bayer AG, the manufacturer of Trasylol, announced in November 2007 that it would stop sales of the drug worldwide due to the increased risk of side effects.
British health group suspends Trasylol sales license
Britain’s Commission on Human Medicines has suspended the sales license for the heart surgery drug Trasylol over safety concerns. Bayer AG, the manufacturer of the drug, decided to stop selling Trasylol in November due to pressure from the Food and Drug Administration and two Canadian studies which had linked the drug to an increased risk of death.
British health group suspends Trasylol sales license
Britain’s Commission on Human Medicines has suspended the sales license for the heart surgery drug Trasylol over safety concerns. Bayer AG, the manufacturer of the drug, decided to stop selling Trasylol in November due to pressure from the Food and Drug Administration and two Canadian studies which had linked the drug to an increased risk of death.
Bayer stops global sales of Trasylol over death risk
Bayer AG says that it will halt worldwide sales of the heart
surgery drug Trasylol due to pressure from the Food and Drug Administration.
The agency says that it asked Bayer to stop sales of Trasylol after a Canadian
study revealed that patients who were given the drug during heart surgery were
at an increased risk of death compared with two similar drugs.
Bayer stops global sales of Trasylol over death risk
Bayer AG says that it will halt worldwide sales of the heart surgery drug Trasylol due to pressure from the Food and Drug Administration. The agency says that it asked Bayer to stop sales of Trasylol after a Canadian study revealed that patients who were given the drug during heart surgery were at an increased risk of death compared with two similar drugs.
FDA plans Trasylol safety review over increased death risk
The Food and Drug Administration says that it will review the safety of a leading heart surgery drug after a major drug trial showed an increased risk of death among patients. Bayer was forced to halt its 3,000 patient study of the heart surgery drug Trasylol after researchers noticed a greater risk of death among patients taking the drug than with two other common anti-clotting drugs used during heart surgery.
Woman files suit against Bayer over Trasylol injuries
A woman has filed suit in U.S. District Court in Tennessee against Bayer Corporation and its parent company, Bayer AG. When Ada M. Williams underwent open-heart surgery, was given Trasylol to limit excessive bleeding. This drug is made and sold by Bayer, but its side effects—not to mention its exorbitant cost—have left the pharmaceutical giant open to criticism and lawsuits like this one.